Herceptin SC (trastuzumab SC)
This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Herceptin (Trastuzumab) SC is a subcutaneous formulation that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Herceptin to be rapidly dispersed and absorbed over a greater area.
Herceptin SC, either alone or in combination with targeted therapies/chemotherapies is indicated for the treatment of patients with HER2-positive early breast cancer (EBC), and metastatic breast cancer (MBC).
If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at [email protected]
In case of any adverse events or safety queries, please contact: [email protected]
If you have a scientific query related to one of Roche's products, please contact: [email protected]
M-PK-00001707
Solutions
Pharma Products
![[Product] Herceptin](https://assets.roche.com/f/169232/768x511/6275c6e311/herceptin.jpg/m/320x180/filters:format(webp):quality(90)/)